Multicenter, USA - 30 Jan `16Incyte: Topical Ruxolitinib for the Treatment of Vitiligo

Official Title: Topical Ruxolitinib for the Treatment of Vitiligo

In Brief: The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.

Description: The hypothesis is that JAK inhibitors can also successfully treat vitiligo. Lesional skin of both alopecia areata and vitiligo primarily contain T cells in a TH1 response as opposed to a mixed cell infiltrate such as in psoriasis or lichen planus. Both alopecia areata and vitiligo are TH1 mediated diseases dependent on the production of IFN-gamma to drive the response. CD8+ T cells are both necessary and sufficient for melanocyte destruction in vitiligo (van den Boorn JG et al 2009) and CD8+NKG2D+ T cells are also necessary and sufficient for hair loss in alopecia areata (Gilhar A et al 2013).

Ages Eligible: 18 Years and older

Start Date: January 2016

Completion Date (estimated): February 2017

Status: Completed

Study ID from ClinicalTrials.gov: NCT02809976 
Other Study ID Numbers: I-18424-15-06 

Location: multicenter, USA

Contact: To learn more about this study, you or your doctor may contact David Rosmarin, MD at Tufts Medical Center. Please refer to this study by its NCT number.

FAQOther Questions

  • Is it possible to stop the progression of vitiligo?

    It is true that vitiligo progression could be stopped in 4 out of 5 cases by the use of potent systemic corticosteroids - that is, oral medications. However, systemic corticost...

  • What is vitiligo?

    Vitiligo (pronounced vit-ill-EYE-go) is a relatively common skin disease characterized by smooth, white, painless spots or patches on various parts of the body and hairs above i...

  • Can chemicals cause vitiligo?

    It’s important to remember there are multiple factors involved in vitiligo onset, including genetic predisposition, living and working environments, and exposure to certain chem...